Welcome to our dedicated page for Cumberland Pharmaceuticals SEC filings (Ticker: CPIX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Cumberland Pharmaceuticals Inc. (CPIX) SEC filings page on Stock Titan aggregates the company’s regulatory disclosures from the U.S. Securities and Exchange Commission, providing a structured view of its financial reporting and material events. As a Nasdaq-listed specialty pharmaceutical company, Cumberland uses these filings to report on its commercial portfolio of FDA-approved brands, clinical programs, and corporate transactions.
Investors can use this page to access annual reports on Form 10-K and quarterly reports on Form 10-Q, which typically include discussions of net revenues by product, research and development spending, liquidity, and risk factors relevant to Cumberland’s hospital acute care, gastroenterology, and oncology businesses. These filings also describe the performance of key brands such as Acetadote, Caldolor, Kristalose, Sancuso, Vaprisol, Vibativ, and Talicia, along with updates on Phase II ifetroban studies in Duchenne Muscular Dystrophy cardiomyopathy, Systemic Sclerosis, and Pulmonary Fibrosis.
The page also lists current reports on Form 8-K, where Cumberland discloses significant events. Recent 8-Ks reference quarterly financial results, strategic arrangements with RedHill Biopharma to jointly commercialize Talicia, and amendments to a revolving credit facility with Pinnacle Bank that outline borrowing capacity, collateral, and covenant terms.
Users can review proxy statements and other governance-related documents to understand board matters and executive compensation, as well as Form 4 insider transaction reports that detail purchases and sales of CPIX shares by officers, directors, and major shareholders.
Stock Titan enhances these filings with AI-powered summaries that highlight key points from lengthy documents, helping readers quickly identify important changes in revenue composition, credit arrangements, clinical program disclosures, and other material information. Real-time updates from EDGAR ensure that new Cumberland filings, including 10-K, 10-Q, 8-K, and Form 4 reports, are added as they become available.
Cumberland Pharmaceuticals Inc. insider A.J. Kazimi has filed a Schedule 13G reporting a significant ownership position in the company’s common stock. Kazimi beneficially owns 5,701,155 shares of Cumberland common stock, representing 38.07% of the outstanding class.
All of these shares are reported with sole voting and sole dispositive power, meaning Kazimi alone can vote and decide whether to sell or hold them. The filing confirms that no other person is identified as sharing voting or investment control over this ownership stake.
Cumberland Pharmaceuticals Inc. reported that the U.S. Food and Drug Administration has granted Fast Track Designation for its novel oral therapy targeting a fatal form of heart disease in patients with Duchenne muscular dystrophy (DMD). This status is intended to speed the development and review of treatments for serious conditions with unmet medical needs. Cumberland furnished a press release with additional details as an exhibit to this report.
Cumberland Pharmaceuticals director Caroline Young reported a series of small open‑market purchases of the company’s common stock in December 2025 under a pre-arranged Rule 10b5-1 trading plan. The filing shows daily acquisitions ranging from
After the final reported purchase on 12/31/2025 at
Cumberland Pharmaceuticals director Kenneth J. Krogulski reported a series of small open-market purchases of the company’s common stock in December 2025. The transactions, coded “L,” were executed under a Rule 10b5-1 trading plan that he adopted on November 14, 2024. Individual daily purchases ranged from dozens of shares at prices in the low single digits per share. The most recent reported transaction was on December 31, 2025, when he bought 62 shares at $3.91 each, bringing his directly held stake to 296,538 common shares following that trade.
Cumberland Pharmaceuticals Inc. entered into an amendment to its revolving credit arrangements with Pinnacle Bank. The amendment keeps the aggregate principal funding available at up to $25 million, with $15 million currently available for borrowing and the right for Cumberland to request an additional $10 million. The revolving line continues to be secured by substantially all of the company’s assets.
The facility includes a quarterly-tested Minimum Fixed Charge Coverage Ratio and Borrowing Base Requirements. Borrowings will bear interest at Benchmark Term SOFR plus 2.75%. The amendment also extends the credit facility’s maturity to October 1, 2027, giving Cumberland a longer-dated source of revolving liquidity.
Cumberland Pharmaceuticals (CPIX) filed its Q3 2025 report, showing quarterly net revenue of
Sancuso delivered
Operating cash flow turned positive at
After quarter end, Cumberland and RedHill formed a joint company to co‑commercialize Talicia in the U.S., with Cumberland committing
Cumberland Pharmaceuticals Inc. filed a current report to furnish a press release dated November 4, 2025. The press release provides a company update and the financial results for the three and nine months ended September 30, 2025. The information is furnished under Item 2.02 regarding results of operations and financial condition and is not deemed filed for liability purposes under Section 18 of the Exchange Act unless later specifically incorporated by reference.
Cumberland Pharmaceuticals (CPIX) — insider share acquisitions reported. Director Caroline Young disclosed a series of automatic purchases executed under a Rule 10b5-1 trading plan.
The filing lists acquisitions of 6 shares on multiple trading days from October 1–31, 2025, at prices ranging from $3.14 to $3.63. Following the final reported transaction on October 31, 2025, the director beneficially owned 33,168 shares, held directly. The transactions were made pursuant to a 10b5-1 plan adopted on November 14, 2024.
Cumberland Pharmaceuticals (CPIX) director James Jones reported automatic open‑market purchases under a Rule 10b5‑1 trading plan. The filings show purchases of 13 shares on each trading day from October 1–31, 2025, at prices ranging from $3.14 to $3.63. Following these transactions, Jones beneficially owns 44,491 shares, held direct.
The Rule 10b5‑1 plan was adopted on November 14, 2024. No derivative securities were reported.
Cumberland Pharmaceuticals (CPIX) reported insider acquisitions by Chairman & CEO A.J. Kazimi on a Form 4. The filing lists a series of 13-share purchases on multiple days from 10/01/2025 through 10/31/2025, executed under a Rule 10b5-1 trading plan.
Reported prices ranged from $3.14 to $3.63 per share across the period. Following the latest transaction, Kazimi’s direct beneficial ownership is 5,700,583 shares.
FAQ
What is the current stock price of Cumberland Pharmaceuticals (CPIX)?
What is the market cap of Cumberland Pharmaceuticals (CPIX)?
